Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and Additions to its Board of Directors
Published on 08/07/2025 at 18:04 | prnewswire.co.uk
Tenmile and Novo Holdings are core investorsCristina Larkin, Bruce Montgomery, and Michael Lamprecht to join the Board of DirectorsRevagenix, Inc. is advancing a focused pipeline of antibiotic programs designed to treat infections caused by multidrug-resistant organismsView original content:https://www.prnewswire.co.uk/news-releases/revagenix-inc-announces-series-b-financing-to-develop-novel-antibiotics-and-additions-to-its-board-of-directors-302027197.html
en | boerse | 67988843 |
